Vesicor Therapeutics Joins Forces with Black Hawk Acquisition
Deal News | Apr 28, 2025 | Globenewswire
Vesicor Therapeutics, Inc., a budding biotechnology firm specializing in the development of p53-based cancer treatments, is set to merge with Black Hawk Acquisition Corporation in a transaction that values Vesicor at a pre-money equity value of $70 million. The merger is anticipated to finalize by Q4 2025 and will list the combined entity on Nasdaq as Vesicor Therapeutics. Vesicor’s ecm-RV/p53 drug candidate, which has been utilized under Japan's Advanced Medical Care B system, is scheduled for preclinical testing in the U.S. The strategic partnership aims to expedite Vesicor's access to capital markets, facilitating further drug development and eventual clinical trials. Black Hawk's subsidiary, BH Merger Sub, Inc., will merge with Vesicor, transforming it into a wholly-owned entity under Black Hawk's umbrella. The transaction, requiring regulatory and shareholder consent, underscores an effort by Black Hawk CEO Kent Kaufman to spotlight firms that promise to revolutionize an industry through innovation and growth.
Sectors
- Biotechnology
- Pharmaceuticals
- Financial Services
Geography
- United States – The primary countries involved in this article include the United States, where Vesicor Therapeutics is based and where future clinical trials and regulatory applications are planned.
- Japan – Japan is significant here as Vesicor’s drug has been administratively utilized there under Japan’s Advanced Medical Care B system before U.S. trials.
Industry
- Biotechnology – The core focus of the article is on biotechnology, specifically in the development of cancer therapeutics involving genetic engineering and RNA technology in Vesicor’s innovative drug methodologies.
- Pharmaceuticals – The article discusses the development of pharmaceutical treatments, emphasizing Vesicor's progression from advanced stages of drug testing in Japan to anticipated trials in the United States.
- Financial Services – Black Hawk Acquisition Corp., a special purpose acquisition company (SPAC) operating within the financial services sector, plays a significant role in facilitating the merger with Vesicor Therapeutics.
Financials
- $70 million – The pre-money equity value of Vesicor Therapeutics as determined for the SPAC merger with Black Hawk Acquisition Corporation.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Vesicor Therapeutics, Inc. | Target Company | Company | An early development stage biotechnology company focused on p53-based cancer therapeutics using precision-engineered microvesicles. |
| Black Hawk Acquisition Corporation | Bidding Company | Company | A special purpose acquisition company (SPAC) aiming to merge with promising companies, enabling them to access public capital markets. |
| BH Merger Sub, Inc. | Merger Subsidiary | Company | A wholly-owned subsidiary of Black Hawk created specifically to merge with Vesicor. |
| Luo Feng, Ph.D. | Founder and CEO | Person | Founder and CEO of Vesicor Therapeutics, pioneering in cancer therapeutics utilizing advanced microvesicle-based delivery systems. |
| Kent Kaufman | CEO | Person | Chief Executive Officer and Chairman of Black Hawk Acquisition, instrumental in orchestrating the merger between Black Hawk and Vesicor. |